GERN
Price
$1.30
Change
-$0.09 (-6.47%)
Updated
Aug 7, 04:59 PM (EDT)
Capitalization
885.32M
91 days until earnings call
SYRE
Price
$15.14
Change
-$0.82 (-5.14%)
Updated
Aug 7, 04:56 PM (EDT)
Capitalization
964M
91 days until earnings call
Interact to see
Advertisement

GERN vs SYRE

Header iconGERN vs SYRE Comparison
Open Charts GERN vs SYREBanner chart's image
Geron
Price$1.30
Change-$0.09 (-6.47%)
Volume$170.66K
Capitalization885.32M
Spyre Therapeutics
Price$15.14
Change-$0.82 (-5.14%)
Volume$2.76K
Capitalization964M
GERN vs SYRE Comparison Chart in %
Loading...
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GERN vs. SYRE commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GERN is a Hold and SYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (GERN: $1.39 vs. SYRE: $15.96)
Brand notoriety: GERN and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GERN: 279% vs. SYRE: 105%
Market capitalization -- GERN: $885.32M vs. SYRE: $964M
GERN [@Biotechnology] is valued at $885.32M. SYRE’s [@Biotechnology] market capitalization is $964M. The market cap for tickers in the [@Biotechnology] industry ranges from $210.97B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GERN’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • GERN’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, SYRE is a better buy in the long-term than GERN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GERN’s TA Score shows that 5 TA indicator(s) are bullish while SYRE’s TA Score has 3 bullish TA indicator(s).

  • GERN’s TA Score: 5 bullish, 5 bearish.
  • SYRE’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, GERN is a better buy in the short-term than SYRE.

Price Growth

GERN (@Biotechnology) experienced а +26.36% price change this week, while SYRE (@Biotechnology) price change was -7.69% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.15%. For the same industry, the average monthly price growth was +8.44%, and the average quarterly price growth was +12.41%.

Reported Earning Dates

GERN is expected to report earnings on Nov 06, 2025.

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+1.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($964M) has a higher market cap than GERN($885M). SYRE YTD gains are higher at: -31.443 vs. GERN (-60.734). GERN has higher annual earnings (EBITDA): -114.49M vs. SYRE (-214.36M). SYRE has more cash in the bank: 565M vs. GERN (397M). SYRE has less debt than GERN: SYRE (0) vs GERN (122M). GERN has higher revenues than SYRE: GERN (116M) vs SYRE (0).
GERNSYREGERN / SYRE
Capitalization885M964M92%
EBITDA-114.49M-214.36M53%
Gain YTD-60.734-31.443193%
P/E RatioN/A1.72-
Revenue116M0-
Total Cash397M565M70%
Total Debt122M0-
FUNDAMENTALS RATINGS
GERN vs SYRE: Fundamental Ratings
GERN
SYRE
OUTLOOK RATING
1..100
6969
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
9255
P/E GROWTH RATING
1..100
7683
SEASONALITY SCORE
1..100
n/a19

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SYRE's Valuation (74) in the Pharmaceuticals Major industry is in the same range as GERN (92) in the Biotechnology industry. This means that SYRE’s stock grew similarly to GERN’s over the last 12 months.

SYRE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as GERN (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to GERN’s over the last 12 months.

GERN's SMR Rating (97) in the Biotechnology industry is in the same range as SYRE (99) in the Pharmaceuticals Major industry. This means that GERN’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's Price Growth Rating (55) in the Pharmaceuticals Major industry is somewhat better than the same rating for GERN (92) in the Biotechnology industry. This means that SYRE’s stock grew somewhat faster than GERN’s over the last 12 months.

GERN's P/E Growth Rating (76) in the Biotechnology industry is in the same range as SYRE (83) in the Pharmaceuticals Major industry. This means that GERN’s stock grew similarly to SYRE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GERNSYRE
RSI
ODDS (%)
Bullish Trend 2 days ago
78%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 4 days ago
74%
Bullish Trend 16 days ago
85%
Declines
ODDS (%)
Bearish Trend 9 days ago
77%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BBTLX15.780.08
+0.51%
Bridge Builder Tax Managed Large Cap
HUDIX24.73N/A
N/A
Huber Large Cap Value Inv
SSMOX10.99N/A
N/A
Steward Values Enhanced SmMidCapR6
JFACX36.98N/A
N/A
JHancock Fundamental All Cap Core R2
TEMHX9.00N/A
N/A
Nuveen Emerging Markets Eq I

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with IDYA. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-5.39%
IDYA - SYRE
60%
Loosely correlated
-2.03%
CGON - SYRE
58%
Loosely correlated
-6.12%
BEAM - SYRE
58%
Loosely correlated
-2.14%
XNCR - SYRE
57%
Loosely correlated
-5.79%
IMNM - SYRE
55%
Loosely correlated
-3.59%
More